Management of Mood Disorders
The Advanced Certificate Program:
Home
Sign In
About
Curriculum
Additional Information
Target Audience
Program Goal
Learning Objectives
CME Information
CME
Contract
Disclosures
Faculty
Roster
Disclosures
Technical Requirements
Update Profile
Contact Us
Keep up to date with us via twitter!
Projects In Knowledge
Overlook at Great Notch
150 Clove Road
Little Falls, NJ 07424
Tel: (973) 890-8988
Fax: (973) 890-8866
| Curriculum I Roster | |||
Chair |
|||
|
Dwight L. Evans, MD Ruth Meltzer Professor and Chairman Professor of Psychiatry, Medicine, and Neuroscience University of Pennsylvania School of Medicine Psychiatrist-in-Chief University of Pennsylvania Health System Philadelphia, Pennsylvania |
||
Faculty |
|||
|
A. John Rush, MD Professor of Psychiatry and Clinical Sciences Vice Chair, Department of Clinical Sciences University of Texas Southwestern Medical Center Dallas, Texas |
|
Michael E. Thase, MD Professor of Psychiatry Director, Mood and Anxiety Disorders Treatment and Research Program Department of Psychiatry University of Pennsylvania Philadelphia, Pennsylvania |
| top | |||
Disclosure Information |
|||
| Dwight L. Evans, MD has received grant/research support from the National Institute of Mental Health; and is a consultant for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb/Otsuka, Eli Lilly and Company, Forest Pharmaceuticals, Inc, Neuronetics, Inc, Pamlab, LLC, and Wyeth Pharmaceuticals. | |||
| A. John Rush, MD has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc. | |||
| Michael E. Thase, MD has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc. | |||
| top | |||
|
These independent CME activities are supported by educational grants from
Pfizer Inc. Additional funding provided by Projects In Knowledge |
|
Take your knowledge to the next level with this highly engaging Certificate Program! 
|
||
|
||
|
||
|
|
Faculty
